Funder: Cures Within Reach
Due Dates (Anticipated): April 2027 (LOI, projected)
Funding Amounts: Up to US$70,000 for a trial plus up to US$8,500 for community engagement; maximum 36 months
Summary: ReGRoW supports underresourced researchers in low and lower-middle income countries testing repurposed therapies for unsolved diseases.
Key Information: Both the PI and institution must be based in eligible countries, and the institution must have prior external clinical research funding.
Description
Cures Within Reach’s ReGRoW—Repurposing Grants for the Rest of the World—supports clinical research led by underresourced scientists and clinicians in low and lower-middle income countries (LMICs). The program aims to build local research capacity while finding available, affordable treatments for patients in those countries. It funds interventional human trials of generic drugs, nutraceuticals, indigenous medicines and combinations used for new indications or added to standard care.
The program accepts any unsolved disease, with a strong preference for high-burden conditions: communicable and non-communicable diseases, maternal, neonatal and nutritional diseases, and injuries. Priorities include proof-of-concept, pivotal, Phase I and Phase IIA trials supported by scientific evidence or clinical observations. Trials should produce reproducible clinical impact or data that support further trials and follow-on funding.
